May 16, 2022
Life Sciences
  • Novavax officials said they are confident that the Food and Drug Administration (FDA) will grant their COVID-19 vaccine an emergency use authorization early next month. Novavax received $1.6 billion from the federal government to speed the development of the shots early during the pandemic but has yet to make it to the U.S. market. A key FDA advisory committee is scheduled to review the company’s request on June 7. (Article here)